Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2023-03-17 00:00:00 ET · period of report 2023-03-16 · accession 0001062993-23-007225 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-17 | 2023-03-16 | ENTA | Vance Terry | Dir | M - OptEx | $14.00 | +5,800 | 21.1K | +38% | +$81.2K |
| D | 2023-03-17 | 2023-03-16 | ENTA | Vance Terry | Dir | M - OptEx | $0.00 | -5,800 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-16 | M | A | 5,800 | $14.00 | 21,095 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-03-16 | M | D | 5,800 | $0.00 | 0 | D | $14.00 · — to 2023-03-20 | 5,800 Common Stock | (F1) 100% of the shares subject to the option are fully vested and exercisable. |